SUBSCRIBE
SUBSCRIBE
News   Drug Development

Ark Therapeutics’ Phase III Brain Cancer Drug Trial Cleared To Continue Update

January 5, 2007 | 
1 min read

LONDON (AFX) - Ark Therapeutics Group PLC’s final-stage trial of an experimental drug to treat brain cancer has been cleared to continue without modification, by Europe’s medicine safety board.

Clinical research Phase III Regulatory Europe
MORE ON THIS TOPIC
Creative photo poster picture collage collapsing dollar banknote arm holding cash money bankrupt decrease income funds loss.
Government
FDA Faces ‘Catastrophic Collapse’ as Massive Layoffs Endanger User Fee Program
April 4, 2025
 · 
3 min read
 · 
Tristan Manalac
Amgen sign at its headquarters in Thousand Oaks, California, USA.
Approvals
Amgen Wins Expansion for Uplizna as First Drug for IgG4-Related Disease
April 4, 2025
 · 
2 min read
 · 
Tristan Manalac
IV infusion set on light blue background, top view. Space for text
Pipeline
BeiGene Scraps TIGIT Candidate After Underwhelming Lung Cancer Data
April 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Brain , concept idea art of thinking, surreal portrait painting, conceptual artwork, 3d illustration
Neurodegenerative disease
Denali Goes All In on Neuroscience’s Thorniest Hurdle: Crossing the Blood-Brain Barrier
April 2, 2025
 · 
5 min read
 · 
Dan Samorodnitsky